BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

208 related articles for article (PubMed ID: 22172904)

  • 1. Incidence of secondary cancer development after high-dose intensity-modulated radiotherapy and image-guided brachytherapy for the treatment of localized prostate cancer.
    Zelefsky MJ; Housman DM; Pei X; Alicikus Z; Magsanoc JM; Dauer LT; St Germain J; Yamada Y; Kollmeier M; Cox B; Zhang Z
    Int J Radiat Oncol Biol Phys; 2012 Jul; 83(3):953-9. PubMed ID: 22172904
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Secondary cancers after intensity-modulated radiotherapy, brachytherapy and radical prostatectomy for the treatment of prostate cancer: incidence and cause-specific survival outcomes according to the initial treatment intervention.
    Zelefsky MJ; Pei X; Teslova T; Kuk D; Magsanoc JM; Kollmeier M; Cox B; Zhang Z
    BJU Int; 2012 Dec; 110(11):1696-701. PubMed ID: 22889401
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Commentary on "secondary cancers after intensity-modulated radiotherapy, brachytherapy, and radical prostatectomy for the treatment of prostate cancer: incidence and cause-specific survival outcomes according to the initial treatment intervention." Zelefsky MJ, Pei X, Teslova T, Kuk D, Magsanoc JM, Kollmeier M, Cox B, Zhang Z. Department of Radiation Oncology, Memorial Sloan-Kettering Cancer Center, New York, NY.: BJU Int 2012;110:1696-701. doi: 10.1111/j.1464-410X.2012.11385.x. [Epub 2012 Aug 13].
    Gottschalk A
    Urol Oncol; 2014 Feb; 32(2):209. PubMed ID: 24445290
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of acute and late toxicities for three modern high-dose radiation treatment techniques for localized prostate cancer.
    Mohammed N; Kestin L; Ghilezan M; Krauss D; Vicini F; Brabbins D; Gustafson G; Ye H; Martinez A
    Int J Radiat Oncol Biol Phys; 2012 Jan; 82(1):204-12. PubMed ID: 21167653
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of prostate cancer radiotherapy on the biological behavior and specific mortality of subsequent bladder cancer.
    Guo X; Liu M; Hou H; Liu S; Zhang X; Zhang Y; Wu P; Pang C; Wang J
    Int J Clin Oncol; 2019 Aug; 24(8):957-965. PubMed ID: 30903422
    [TBL] [Abstract][Full Text] [Related]  

  • 6. External Beam Radiotherapy Increases the Risk of Bladder Cancer When Compared with Radical Prostatectomy in Patients Affected by Prostate Cancer: A Population-based Analysis.
    Moschini M; Zaffuto E; Karakiewicz PI; Andrea DD; Foerster B; Abufaraj M; Soria F; Mattei A; Montorsi F; Briganti A; Shariat SF
    Eur Urol; 2019 Feb; 75(2):319-328. PubMed ID: 30293908
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Radiation therapy for prostate cancer increases subsequent risk of bladder and rectal cancer: a population based cohort study.
    Nieder AM; Porter MP; Soloway MS
    J Urol; 2008 Nov; 180(5):2005-9; discussion 2009-10. PubMed ID: 18801517
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Second primary cancer after radiotherapy for prostate cancer--a seer analysis of brachytherapy versus external beam radiotherapy.
    Abdel-Wahab M; Reis IM; Hamilton K
    Int J Radiat Oncol Biol Phys; 2008 Sep; 72(1):58-68. PubMed ID: 18374503
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rates of rectal toxicity in patients treated with high dose rate brachytherapy as monotherapy compared to dose-escalated external beam radiation therapy for localized prostate cancer.
    Parzen JS; Ye H; Gustafson G; Yan D; Martinez A; Chen PY; Ghilezan M; Sebastian E; Limbacher A; Krauss DJ
    Radiother Oncol; 2020 Jun; 147():123-129. PubMed ID: 32276193
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Incidence of second malignancies in prostate cancer patients treated with low-dose-rate brachytherapy and radical prostatectomy.
    Hamilton SN; Tyldesley S; Hamm J; Jiang WN; Keyes M; Pickles T; Lapointe V; Kahnamelli A; McKenzie M; Miller S; Morris WJ
    Int J Radiat Oncol Biol Phys; 2014 Nov; 90(4):934-41. PubMed ID: 25240272
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The impact of age at the time of radiotherapy for localized prostate cancer on the development of second primary malignancies.
    Krasnow RE; Rodríguez D; Nagle RT; Mossanen M; Kibel AS; Chang SL
    Urol Oncol; 2018 Nov; 36(11):500.e11-500.e19. PubMed ID: 30249519
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cancer incidence after localized therapy for prostate cancer.
    Moon K; Stukenborg GJ; Keim J; Theodorescu D
    Cancer; 2006 Sep; 107(5):991-8. PubMed ID: 16878323
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Second malignancies after prostate brachytherapy: incidence of bladder and colorectal cancers in patients with 15 years of potential follow-up.
    Liauw SL; Sylvester JE; Morris CG; Blasko JC; Grimm PD
    Int J Radiat Oncol Biol Phys; 2006 Nov; 66(3):669-73. PubMed ID: 16887293
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The rate of secondary malignancies after radical prostatectomy versus external beam radiation therapy for localized prostate cancer: a population-based study on 17,845 patients.
    Bhojani N; Capitanio U; Suardi N; Jeldres C; Isbarn H; Shariat SF; Graefen M; Arjane P; Duclos A; Lattouf JB; Saad F; Valiquette L; Montorsi F; Perrotte P; Karakiewicz PI
    Int J Radiat Oncol Biol Phys; 2010 Feb; 76(2):342-8. PubMed ID: 20117287
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Risk of second cancers according to radiation therapy technique and modality in prostate cancer survivors.
    Berrington de Gonzalez A; Wong J; Kleinerman R; Kim C; Morton L; Bekelman JE
    Int J Radiat Oncol Biol Phys; 2015 Feb; 91(2):295-302. PubMed ID: 25636756
    [TBL] [Abstract][Full Text] [Related]  

  • 16. External Beam Radiation Therapy With a Brachytherapy Boost Versus Radical Prostatectomy in Gleason Pattern 5 Prostate Cancer: A Population-Based Cohort Study.
    Wang C; Kishan AU; Kamrava M; Steinberg ML; King CR
    Int J Radiat Oncol Biol Phys; 2017 Aug; 98(5):1045-1052. PubMed ID: 28721887
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Modelling second malignancy risks from low dose rate and high dose rate brachytherapy as monotherapy for localised prostate cancer.
    Murray L; Mason J; Henry AM; Hoskin P; Siebert FA; Venselaar J; Bownes P;
    Radiother Oncol; 2016 Aug; 120(2):293-9. PubMed ID: 27370205
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pattern of solid and hematopoietic second malignancy after local therapy for prostate cancer.
    Wang C; King CR; Kamrava M; Iwamoto KS; Chen AM; Low D; Kupelian PA; Steinberg ML
    Radiother Oncol; 2017 Apr; 123(1):133-138. PubMed ID: 28187996
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Intensity-modulated radiotherapy causes fewer side effects than three-dimensional conformal radiotherapy when used in combination with brachytherapy for the treatment of prostate cancer.
    Forsythe K; Blacksburg S; Stone N; Stock RG
    Int J Radiat Oncol Biol Phys; 2012 Jun; 83(2):630-5. PubMed ID: 22099032
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ten-year survival after High-Dose-Rate Brachytherapy combined with External Beam Radiation Therapy in high-risk prostate cancer: A comparison with the Norwegian SPCG-7 cohort.
    Wedde TB; Småstuen MC; Brabrand S; Fosså SD; Kaasa S; Tafjord G; Russnes KM; Hellebust TP; Lilleby W
    Radiother Oncol; 2019 Mar; 132():211-217. PubMed ID: 30389241
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.